Eli Lilly and Company $LLY Shares Acquired by Balboa Wealth Partners

Balboa Wealth Partners raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 5.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,715 shares of the company’s stock after purchasing an additional 93 shares during the quarter. Balboa Wealth Partners’ holdings in Eli Lilly and Company were worth $1,337,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Swan Global Investments LLC increased its stake in shares of Eli Lilly and Company by 26.3% in the second quarter. Swan Global Investments LLC now owns 562 shares of the company’s stock worth $438,000 after acquiring an additional 117 shares during the period. Calamos Wealth Management LLC increased its stake in shares of Eli Lilly and Company by 25.2% in the second quarter. Calamos Wealth Management LLC now owns 38,439 shares of the company’s stock worth $29,965,000 after acquiring an additional 7,748 shares during the period. Parthenon LLC increased its stake in shares of Eli Lilly and Company by 1.0% in the second quarter. Parthenon LLC now owns 5,092 shares of the company’s stock worth $3,969,000 after acquiring an additional 50 shares during the period. Cidel Asset Management Inc. increased its stake in shares of Eli Lilly and Company by 35.0% in the second quarter. Cidel Asset Management Inc. now owns 21,135 shares of the company’s stock worth $16,475,000 after acquiring an additional 5,476 shares during the period. Finally, Chicago Partners Investment Group LLC increased its stake in shares of Eli Lilly and Company by 0.5% in the second quarter. Chicago Partners Investment Group LLC now owns 21,322 shares of the company’s stock worth $17,034,000 after acquiring an additional 111 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 1.9%

LLY stock opened at $803.53 on Monday. The firm has a market cap of $760.51 billion, a PE ratio of 52.52, a P/E/G ratio of 1.15 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm’s fifty day moving average is $753.09 and its 200 day moving average is $765.70. Eli Lilly and Company has a one year low of $623.78 and a one year high of $935.63.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm’s revenue was up 37.6% on a year-over-year basis. During the same quarter last year, the business earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Leerink Partners reiterated a “market perform” rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Guggenheim reiterated a “buy” rating and issued a $948.00 price objective on shares of Eli Lilly and Company in a research note on Thursday. Cantor Fitzgerald set a $925.00 price objective on shares of Eli Lilly and Company and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Berenberg Bank reiterated a “hold” rating and issued a $830.00 price objective (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $939.12.

Insider Buying and Selling at Eli Lilly and Company

In related news, Director J Erik Fyrwald acquired 1,565 shares of the firm’s stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO David A. Ricks acquired 1,632 shares of the firm’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 4,514 shares of company stock valued at $2,894,841. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.